|Dr. Robert Joseph Hariri||Chairman of Board & Chairman of the Scientific Advisory Board||N/A||N/A||1959|
|Mr. Joseph Mannello||CEO & Director||43.36k||N/A||1958|
|Mr. Ren Ren||Global Chairman||N/A||N/A||1962|
|Mr. Joseph DiPietro||Controller||N/A||N/A||N/A|
|Mr. Magshoud Dariani||Chief Technology Officer||N/A||N/A||N/A|
MYOS RENS Technology Inc. focuses on the discovery, development, and commercialization of nutritional and therapeutic products that enhance muscle health and performance. The company primarily focuses on developing products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity. Its products include Qurr line of products comprising flavored puddings, powders, and shakes; Yolked line of products for collegiate and professional athletes; and Myos Canine Muscle Formula line of products for pets. The company sells its products through direct-to-consumer e-commerce platform; and at the Vitamin Shoppe. MYOS RENS Technology Inc. has a research agreement with the University of California to study the effects Of Fortetropin on skeletal muscle protein synthetic rate in older men and women; Rutgers University for the discovery development and commercialization of products that improve muscle health and performance; Weill Cornell Medical College to study the efficacy of Fortetropin in preventing weight and muscle loss associated with cancer; and McMaster University to study impact of Fortetropin on muscle disuse atrophy in young men. The company was formerly known as MYOS Corporation and changed its name to MYOS RENS Technology Inc. in March 2016. MYOS RENS Technology Inc. was founded in 2007 and is based in Cedar Knolls, New Jersey.
MYOS RENS Technology Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.